Margin of Error: The Emerging Role of Field Cancerization in Predicting Recurrence Risk of Ductal Carcinoma In Situ
International Journal of Molecular Sciences · 10.03.2026 · 27 (6) · 2523
DOI: 10.3390/ijms27062523 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.03.2026. Verfasst von Sophia Hu-Lieskovan und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, University of Utah, Salt Lake City, UT 84112, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms. Die Arbeit nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center.
Abstract (Originalsprache)
Although ductal carcinoma in situ (DCIS) diagnoses continue to climb, patient management remains constrained by limitations in recurrence prediction. Conventional histopathology and existing prognostic parameters often inadequately predict local recurrence, leading to over- or under-treatment. Additionally, discourse remains over the clinical implications of margin width as a measure of recurrence risk, demonstrating the limitations of a margin-based model, and motivating our proposal that recurrence risk is dynamic and should be defined by patient-specific, spatially resolved diagnostic biomarkers. This review introduces field cancerization as a framework that may illuminate mechanisms underlying DCIS ipsilateral recurrence and improve clinical decision-making. We propose that the potential drivers of ductal field cancerization span two stages: pre-tumorigenesis and post-tumorigenesis. Pre-tumorigenic events include non-biological and biological exposome factors. Post-tumorigenic drivers include intratumoral and microenvironment-mediated remodeling of adjacent tissues that promote malignancy. This review bridges stage-specific molecular mechanisms to potentially actionable strategies for DCIS patient management—particularly margin assessment and recurrence risk prognostication—while highlighting the critical unmet need to identify biomarkers that measure high-risk field changes. We also emphasize the need to move beyond lesion-centric management toward multivariable prognostic models that include distance-mapped field biomarkers, enabling more precise surgery, improved selection of adjuvant therapy, and safer de-escalation for low-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Sciences, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Biology, Westminster University, Salt Lake City, UT 84105, USA.
- City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
- Science Department, Rowland Hall, Salt Lake City, UT 84102, USA.
ORCID-Profile: Olivia Banks, Nikita Jinna
Förderung
- National Cancer Center
Zitieren
APA
Hu-Lieskovan, S., Banks, O., Davidson, R., Franklin, D., Rida, P., & Jinna, N. (2026). Margin of Error: The Emerging Role of Field Cancerization in Predicting Recurrence Risk of Ductal Carcinoma In Situ. International Journal of Molecular Sciences, 27(6), 2523. https://doi.org/10.3390/ijms27062523
Vancouver
Hu-Lieskovan S, Banks O, Davidson R, Franklin D, Rida P, Jinna N. Margin of Error: The Emerging Role of Field Cancerization in Predicting Recurrence Risk of Ductal Carcinoma In Situ. International Journal of Molecular Sciences. 2026;27(6):2523. doi:10.3390/ijms27062523
BibTeX
@article{HuLieskovan2026,
author = {Hu-Lieskovan, Sophia and Banks, Olivia and Davidson, Rose and Franklin, Dana and Rida, Padmashree and Jinna, Nikita},
title = {Margin of Error: The Emerging Role of Field Cancerization in Predicting Recurrence Risk of Ductal Carcinoma In Situ},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2523},
doi = {10.3390/ijms27062523}
}
EUVIMED